GO:0051344 negative regulation of cyclic-nucleotide phosphodiesterase activity: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051344 describes any process that stops or reduces the rate of cyclic nucleotide phosphodiesterase (PDE) activity, the enzymes that hydrolyze cAMP and cGMP.
• Negative regulation of PDE activity is essential for maintaining cyclic nucleotide signaling thresholds in cardiac, neuronal, and immune cells.
• Key molecular players include A-kinase anchoring proteins, PKA RIα subunit, and PDE isoforms such as PDE3A, PDE4B, and PDE10A.
• Dysregulation of this process is linked to cardiac hypertrophy, heart failure, alcohol use disorder, and peripheral neuropathies.
• CRISPR knockout, point mutation, and overexpression models are powerful tools to dissect causal roles of PDE regulators.
• EDITGENE provides end-to-end CRISPR services to study negative regulation of PDE activity in disease-relevant cell models.
Description
Cyclic nucleotide phosphodiesterases (PDEs) are the sole enzymes that degrade cAMP and cGMP, thereby terminating cyclic nucleotide signaling. The biological process defined by GO:0051344, negative regulation of cyclic-nucleotide phosphodiesterase activity, encompasses any mechanism that reduces or stops this hydrolytic activity. This regulation is critical because excessive PDE activity can blunt cAMP/PKA signaling, while insufficient PDE inhibition can lead to pathological cyclic nucleotide accumulation. Understanding how PDE activity is negatively regulated is therefore central to cardiovascular, neurological, and metabolic research. Recent studies have identified multiple layers of control, including protein-protein interactions, post-translational modifications, and feedback loops involving PKA and PDE isoforms. For example, the A2A receptor-D2 receptor heteromer modulates PDE10A activity in cardiac hypertrophy, illustrating how receptor crosstalk can negatively regulate PDE function. Similarly, the RIα subunit of PKA is essential for fine-tuning cAMP hydrolysis and contractility in the heart. These findings underscore the importance of GO:0051344 in both basic signaling biology and translational medicine.
negative regulation of cyclic-nucleotide phosphodiesterase activity At A Glance
| GO ID | GO:0051344 |
|---|---|
| GO term | negative regulation of cyclic-nucleotide phosphodiesterase activity |
| Ontology | biological_process |
| Synonym | cAMP phosphodiesterase inhibitor; phosphodiesterase inhibitor; negative regulation of cGMP phosphodiesterase activity |
| Major function | Reduces the rate of cAMP and cGMP hydrolysis, thereby modulating cyclic nucleotide signaling |
| Key enzymes | PDE3A, PDE4B, PDE10A, and other phosphodiesterase isoforms |
| Regulatory inputs | PKA RIα subunit, A2A-D2 receptor heteromers, and feedback phosphorylation |
| Disease relevance | Cardiac hypertrophy, heart failure, alcohol drinking behavior, peripheral neuropathies |
What Is GO:0051344?
GO:0051344 is a biological process term that describes any process that stops or reduces the rate of cyclic nucleotide phosphodiesterase activity. Cyclic nucleotide phosphodiesterases catalyze the reaction: nucleotide 3',5'-cyclic phosphate + H2O = nucleotide 5'-phosphate. Thus, negative regulation of this activity leads to decreased hydrolysis of cAMP and cGMP, thereby prolonging or enhancing cyclic nucleotide signaling.
Why Is negative regulation of cyclic-nucleotide phosphodiesterase activity Important in Cell Biology?
Negative regulation of cyclic-nucleotide phosphodiesterase activity is a central control point in cyclic nucleotide signaling. By reducing PDE activity, cells can sustain cAMP and cGMP levels, which in turn regulate cardiac contractility, neuronal excitability, and immune responses. Dysregulation of this process contributes to heart failure, hypertrophy, and addiction-related behaviors, making it a prime target for therapeutic intervention.
• Maintains cAMP/PKA signaling thresholds in cardiomyocytes, influencing contractility and remodeling.
• Modulates cardiac hypertrophy through A2A receptor-D2 receptor heteromer-PDE10A axis.
• Regulates alcohol drinking behavior via PDE-dependent cAMP signaling in reward circuits.
• Involved in peripheral neuropathies through altered 2',3'-cyclic nucleotide phosphodiesterase expression.
• Impacts redox regulation and stress responses, as shown by heterologous PDE3A expression in yeast.
• Affects erythropoiesis by modulating gamma-globin gene expression via cAMP-dependent pathways.
• Provides a mechanism for cross-talk between G-protein coupled receptors and cyclic nucleotide pools.
• Offers therapeutic targets for heart failure, addiction, and neurodegenerative conditions.
• Enables fine-tuning of immune cell responses through cAMP gradients.
• Serves as a paradigm for understanding enzyme inhibition in signaling networks.
What Happens During negative regulation of cyclic-nucleotide phosphodiesterase activity?
Initiation by upstream signals
In simple terms: A signal from outside the cell starts the process.
Negative regulation of PDE activity often begins with receptor activation. For instance, A2A receptor-D2 receptor heteromerization recruits PDE10A and modulates its activity in cardiac hypertrophy models. Similarly, beta-adrenergic stimulation can trigger feedback phosphorylation of PDEs, reducing their catalytic rate.
Direct inhibition of PDE catalytic domain
In simple terms: Molecules bind to the enzyme and block its action.
Small molecules or proteins can directly bind to the catalytic domain of PDEs, preventing cAMP or cGMP hydrolysis. The RIα subunit of PKA interacts with PDEs to fine-tune cAMP levels, as shown in heart failure models. In yeast, heterologous expression of human PDE3A alters redox regulation, indicating that direct modulation of PDE activity affects cellular metabolism.
Post-translational modifications
In simple terms: Chemical tags on the enzyme change its activity.
Phosphorylation and other modifications can reduce PDE activity. For example, PKA-mediated phosphorylation of PDE4B blunts beta-adrenergic responses and maladaptive remodeling in heart failure. Such modifications create feedback loops that dynamically regulate cyclic nucleotide pools.
Downstream effects on cyclic nucleotide signaling
In simple terms: Blocking the enzyme increases cAMP or cGMP, changing cell behavior.
When PDE activity is reduced, cAMP and cGMP accumulate, activating effectors such as PKA, EPAC, and cGMP-dependent protein kinases. This can alter gene expression, contractility, and cell survival. In erythroid cells, cAMP-dependent pathways negatively regulate gamma-globin gene expression, linking PDE inhibition to hemoglobin switching.
Feedback and termination
In simple terms: The cell resets the system to avoid overstimulation.
Prolonged PDE inhibition can trigger compensatory increases in PDE expression or activity. For example, chronic alcohol exposure alters PDE regulation in reward circuits, leading to neuroadaptation. Similarly, in peripheral neuropathies, 2',3'-cyclic nucleotide phosphodiesterase gene expression is dynamically regulated.
Key Genes Involved in GO:0051344 negative regulation of cyclic-nucleotide phosphodiesterase activity
The following genes and proteins are central to the negative regulation of cyclic-nucleotide phosphodiesterase activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE3A | Hydrolyzes cAMP and cGMP; inhibited by regulatory inputs | Redox regulation in yeast; cardiovascular studies |
| PDE4B | cAMP-specific phosphodiesterase; feedback regulation by PKA | Heart failure and beta-adrenergic remodeling |
| PDE10A | Dual cAMP/cGMP phosphodiesterase; modulated by receptor heteromers | Cardiac hypertrophy via A2A-D2 receptor crosstalk |
| PRKAR1A | RIα subunit of PKA; regulates PDE activity and contractility | Heart failure development |
| ADORA2A | A2A adenosine receptor; forms heteromers with D2R | Modulates PDE10A in cardiac hypertrophy |
| DRD2 | D2 dopamine receptor; heteromerizes with A2A receptor | PDE10A-mediated cardiac hypertrophy |
| CNP | 2',3'-cyclic nucleotide phosphodiesterase; regulated in neuropathies | Peripheral neuropathy models |
| PDE4D | cAMP phosphodiesterase; involved in alcohol drinking | Addiction research |
| PDE1 | Calcium/calmodulin-dependent PDE; negative regulation by calcium signals | Neuronal signaling |
| PDE2 | cGMP-stimulated PDE; regulated by cGMP levels | Cardiovascular and neuronal studies |
| PDE5 | cGMP-specific PDE; target of inhibitors | Erectile dysfunction and pulmonary hypertension |
| PDE7 | cAMP-specific PDE; high affinity for cAMP | Immune and inflammatory studies |
| PDE8 | cAMP-specific PDE; involved in T-cell activation | Immunology |
| PDE9 | cGMP-specific PDE; role in cognition | Neurodegeneration |
| PDE11 | Dual cAMP/cGMP PDE; tissue-specific | Reproductive and neuronal studies |
| TIR domain proteins | Synthesize 2',3'-cAMP/cGMP; indirectly affect PDE regulation | Plant immunity and cell death |
How Is negative regulation of cyclic-nucleotide phosphodiesterase activity Regulated?
The process of negative regulation of PDE activity is itself regulated by multiple mechanisms. PKA RIα subunit availability controls the extent of PDE inhibition in the heart. Receptor heteromerization, such as A2A-D2, dynamically modulates PDE10A activity. Feedback phosphorylation of PDE4B by PKA creates a negative feedback loop that blunts beta-adrenergic signaling. Additionally, chronic alcohol exposure alters PDE regulation in reward circuits, indicating neuroadaptive regulation.
negative regulation of cyclic-nucleotide phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE10A | Cardiac hypertrophy | Cardiomyocyte-specific knockout or overexpression |
| PDE4B | Heart failure | Cardiac overexpression in mouse models |
| PRKAR1A | Heart failure | Inducible cardiomyocyte knockout |
| PDE4D | Alcohol use disorder | Brain-specific knockdown or knockout |
| CNP | Peripheral neuropathy | Nerve injury models with knockout |
Cardiac hypertrophy and heart failure
Negative regulation of PDE activity is critical in the heart. A2A receptor-D2 receptor heteromers modulate PDE10A, and disruption of this regulation leads to cardiac hypertrophy. Overexpression of PDE4B blunts beta-adrenergic responses and reduces maladaptive remodeling in heart failure. The PKA RIα subunit is essential for regulating contractility and heart failure development.
Alcohol use disorder
PDE regulation in reward circuits influences alcohol drinking behavior. Rodent studies show that modulating PDE activity alters alcohol consumption, suggesting that negative regulation of PDEs may be protective or maladaptive depending on context.
Peripheral neuropathies
2',3'-cyclic nucleotide phosphodiesterase gene expression is regulated in experimental peripheral neuropathies, linking PDE regulation to nerve injury and repair.
Erythropoiesis and hemoglobin switching
cAMP-dependent pathways negatively regulate gamma-globin gene expression in erythroid cells, implicating PDE regulation in hemoglobin disorders.
From negative regulation of cyclic-nucleotide phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PDE10A inhibition prevent cardiac hypertrophy? | Cardiomyocyte-specific PDE10A knockout or knock-in |
| How does PDE4B overexpression affect beta-adrenergic signaling? | Cardiac-specific PDE4B overexpression |
| What is the role of PKA RIα in contractility? | Inducible PRKAR1A knockout in heart |
| Does PDE4D regulate alcohol drinking? | PDE4D knockout or knockdown in reward circuits |
| How is CNP regulated in neuropathy? | CNP knockout or reporter knock-in in nerve injury models |
| Can PDE3A modulation alter redox balance? | Heterologous expression in yeast |
How to Study the negative regulation of cyclic-nucleotide phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PDE activity assay | Rate of cAMP/cGMP hydrolysis | Testing inhibitors or regulatory proteins |
| CRISPR knockout | Loss of gene function | Determining causal role of PDEs |
| Overexpression | Increased protein levels | Modeling pathological PDE upregulation |
| Phosphoproteomics | Phosphorylation changes | Identifying feedback regulation |
| RNA-seq | Transcriptional changes | Assessing downstream effects |
| FRET biosensors | Real-time cAMP/cGMP dynamics | Live-cell imaging of PDE regulation |
| Yeast heterologous expression | Redox and growth phenotypes | Functional study of human PDE3A |
CRISPR knockout and point mutation
CRISPR-Cas9 can generate knockout or point mutations in PDE genes to test their role in negative regulation. For example, knocking out PDE10A in cardiomyocytes can reveal its contribution to hypertrophy. Point mutations in the catalytic domain can dissect residues required for inhibition.
Overexpression and knock-in models
Overexpressing PDE4B in the heart blunts beta-adrenergic responses, demonstrating the impact of increased PDE activity. Knock-in of tagged PDEs allows tracking of localization and interactions.
Biochemical assays for PDE activity
Cyclic nucleotide hydrolysis can be measured using radioactive or fluorescent substrates. Such assays quantify the negative regulation of PDE activity in response to inhibitors or regulatory proteins.
Transcriptomics and proteomics
RNA-seq and proteomics can identify changes in PDE expression and post-translational modifications under conditions of negative regulation. For instance, PKA RIα knockout alters the cardiac transcriptome.
How CRISPR Can Be Used to Study GO:0051344 negative regulation of cyclic-nucleotide phosphodiesterase activity
Knockout
CRISPR knockout of PDE genes or their regulators can abolish negative regulation, leading to elevated cyclic nucleotide levels. For example, PDE10A knockout in cardiomyocytes may prevent hypertrophy. Knockout of PRKAR1A disrupts contractility.
Point Mutation
Point mutations in the catalytic domain of PDEs can render them insensitive to inhibition, allowing precise mapping of regulatory sites. Such models are valuable for drug discovery.
Knock-in
Knock-in of tagged or mutant PDEs enables tracking of protein localization and interactions in vivo. For instance, tagging PDE4B can reveal its subcellular distribution during heart failure.
Overexpression
CRISPR activation or transgenic overexpression of PDEs can mimic pathological states. Overexpressing PDE4B in the heart blunts beta-adrenergic signaling and reduces remodeling.
How EDITGENE Supports negative regulation of cyclic-nucleotide phosphodiesterase activity Research
Researchers studying negative regulation of cyclic-nucleotide phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in disease phenotypes or whether it merely correlates with them. EDITGENE provides the necessary CRISPR tools to establish causality.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cyclic-nucleotide phosphodiesterase activity research.
Frequently Asked Questions About negative regulation of cyclic-nucleotide phosphodiesterase activity
What is GO:0051344?
GO:0051344 is the Gene Ontology term for negative regulation of cyclic-nucleotide phosphodiesterase activity, describing any process that reduces the rate of cAMP or cGMP hydrolysis.
What genes are involved in negative regulation of cyclic-nucleotide phosphodiesterase activity?
Key genes include PDE3A, PDE4B, PDE10A, PRKAR1A, ADORA2A, DRD2, and CNP, among others.
How does negative regulation of PDE activity affect the heart?
It modulates cAMP/PKA signaling, influencing contractility, hypertrophy, and heart failure progression.
What diseases are linked to dysregulated PDE inhibition?
Cardiac hypertrophy, heart failure, alcohol use disorder, and peripheral neuropathies are associated with altered PDE regulation.
What experimental models are used to study this process?
CRISPR knockout, point mutation, knock-in, and overexpression models in cardiomyocytes, neurons, and yeast are commonly used.
How can I measure negative regulation of PDE activity?
PDE activity assays, FRET biosensors, and phosphoproteomics can quantify changes in cAMP/cGMP hydrolysis and regulatory phosphorylation.
Is PDE10A a good target for cardiac hypertrophy?
Studies show that A2A-D2 receptor heteromers modulate PDE10A, and targeting this axis may prevent hypertrophy.
What is the role of PKA RIα in PDE regulation?
The RIα subunit of PKA is essential for fine-tuning cAMP hydrolysis and maintaining cardiac contractility.
Can CRISPR screens identify new regulators of PDE activity?
Yes, genome-wide CRISPR screens can uncover novel genes that negatively regulate PDE activity.
What services does EDITGENE offer for PDE research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
Negative regulation of cyclic-nucleotide phosphodiesterase activity (GO:0051344) is a fundamental process that controls cAMP and cGMP signaling in health and disease. Key regulators such as PDE10A, PDE4B, and PKA RIα have been implicated in cardiac hypertrophy, heart failure, and addiction. Understanding this process requires robust experimental models, and CRISPR-based approaches offer precise tools to dissect causality. EDITGENE stands ready to support your research with tailored CRISPR services.
References
- 1. Yu D et al.. 2022. TIR domains of plant immune receptors are 2',3'-cAMP/cGMP synthetases mediating cell death.. Cell 185(13):2370-2386.e18 PMID: 35597242
- 2. Chen S et al.. 2025. Role of A(2A)R-D2R Dimerization and D(2)R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.. Circulation 152(19):1371-1392 PMID: 40970278
- 3. Bedioune I et al.. 2024. Essential Role of the RIα Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development.. Circulation 150(25):2031-2045 PMID: 39355927
- 4. Logrip ML. 2015. Phosphodiesterase regulation of alcohol drinking in rodents.. Alcohol 49(8):795-802 PMID: 26095589
- 5. LeBlanc AC et al.. 1992. Regulation of 2',3'-cyclic nucleotide phosphodiesterase gene expression in experimental peripheral neuropathies.. Brain Res Mol Brain Res 15(1-2):40-6 PMID: 1279349
- 6. Karam S et al.. 2020. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.. Circulation 142(2):161-174 PMID: 32264695
- 7. Rhee DK et al.. 2016. Effects of heterologous expression of human cyclic nucleotide phosphodiesterase 3A (hPDE3A) on redox regulation in yeast.. Biochem J 473(22):4205-4225 PMID: 27647936
- 8. Inoue A et al.. 2004. Negative regulation of gamma-globin gene expression by cyclic AMP-dependent pathway in erythroid cells.. Exp Hematol 32(3):244-53 PMID: 15003309
